Explore the vast range of titles available.

The DANHEART trial is a multicenter, randomized (1:1), parallel-group, double-blind, placebo-controlled study in chronic heart failure patients with reduced ejection fraction (HFrEF). This investigator driven study will include 1500 HFrEF patients and test in a 2 × 2 factorial design: 1) if hydralazine-isosorbide dinitrate reduces the incidence of death and hospitalization with worsening heart failure vs. placebo (H-HeFT) and 2) if metformin reduces the incidence of death, worsening heart failure, acute myocardial infarction, and stroke vs. placebo in patients with diabetes or prediabetes (Met-HeFT). Symptomatic, optimally treated HFrEF patients with LVEF ≤40% are randomized to active vs. placebo treatment. Patients can be randomized in either both H-HeFT and Met-HeFT or to only one of these study arms. In this event-driven study, it is anticipated that 1300 patients should be included in H-HeFT and 1100 in Met-HeFT and followed for an average of 4 years. As of May 2020, 296 patients have been randomized at 20 centers in Denmark. The H-HeFT and Met-HeFT studies will yield new knowledge about the potential benefit and safety of 2 commonly prescribed drugs with limited randomized data in patients with HFrEF.

Acute lung injury is a frequent and treatment-limiting consequence of therapy with 100% oxygen. Previous studies have determined that both interleukin (IL)-6 and IL-11 are protective in oxygen toxicity. This protection was associated with markedly diminished alveolar–capillary protein leak, endothelial and epithelial membrane injury, lipid peroxidation, and pulmonary neutrophil recruitment. Hyperoxia also caused cell death with DNA fragmentation in the lungs of transgene (−) animals, and both IL-6 and IL-11 markedly diminished this cell death response. However, the mechanism(s) by which these cytokines protect cells from death is unclear. In the present study, we characterized the effects of H2O2 on subconfluent human umbilical vein endothelial cell (HUVEC) and human pulmonary microvascular endothelial cell (HPMEC) cultures. We found that preincubation of HUVEC cultures with either IL-6 or IL-11 diminished H2O2 (1.0 mM)-induced cell death. Similar effects were noted with HPMEC showing that this effect is not HUVEC-specific. The protective effects of both IL-6 and IL-11 were not associated with any changes in antioxidants and were decreased by ∼ 80% in the presence of U0126, a specific inhibitor of MEK-1–dependent pathways. The cytoprotective effects of IL-11 and IL-6 were also completely eliminated in STAT3 dominant-negative transduced HUVEC cultures. These studies demonstrate that IL-6 and IL-11 both confer cytoprotective effects that diminish oxidant-mediated endothelial cell injury. They also demonstrate that this protection is mediated, at least in part, by a STAT3 and MEK-1–dependent specific signal transduction pathway(s).

The production rates of prompt and non-prompt J/psi and psi(2S) mesons in their dimuon decay modes are measured using 2.1 and 11.4 fb(-1) of data collected with the ATLAS experiment at the Large Hadron Collider, in proton-proton collisions at root s = 7 and 8 respectively. Production cross-sections for prompt as well as non-prompt sources, ratios of psi(2S) to J/psi production, and the fractions of non-prompt production for J/psi and psi(2S) are measured as a function of meson transverse momentum and rapidity. The measurements are compared to theoretical predictions.

The differential cross section for the processZ/γ^(*)→ ll( l=e,μ ) as a function of dilepton invariant mass is measured in pp collisions at√s̅= 7 TeV at the LHC using the ATLAS detector. The measurement is performed in theeandμchannels for invariant masses between 26 GeV and 66 GeV using an integrated luminosity of 1.6 fb ⁻¹collected in 2011 and these measurements are combined. The analysis is extended to invariant masses as low as 12 GeV in the muon channel using 35 pb ⁻¹of data collected in 2010. The cross sections are determined within fiducial acceptance regions and corrections to extrapolate the measurements to the full kinematic range are provided. Next-to-next-to-leading-order QCD predictions provide a significantly better description of the results than next-to-leading-order QCD calculations, unless the latter are matched to a parton shower calculation.